statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clene Inc. (NASDAQ:CLNN  Free Report)  Investment analysts at Roth Capital decreased their Q1 2024 earnings per share (EPS) estimates for Clene in a report issued on Wednesday, March...

Roth Capital Equities Analysts Cut Earnings Estimates for Clene Inc. (NASDAQ:CLNN)

LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that...

IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Clene announces peer-reviewed publication on CNM-Au8

Proprietary catalytic gold nanocrystals comprising Clene's investigational drug CNM-Au8 develop a protein corona upon exposure to human blood plasma comprised of proteins that promote blood-brain...

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8

Clene ( NASDAQ:CLNN ) Full Year 2023 Results Key Financial Results Net loss: US$49.5m (loss widened by 66% from FY...

Clene Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Clene expects cash to fund operations into 4Q24

Clene reports 2023 EPS (47c), consensus (45c)

Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8 for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label...

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Clene: Q4 Earnings Insights

SALT LAKE CITY, March 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene ) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...

Clene to Present at the 36th Annual ROTH Conference

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Volume	310,225.00
52-Wk High	$1.09
52-Wk Low	$0.25

CLNN Clene Inc

About

Feed

News

Sentiment

Earnings

Fundamentals